241 related articles for article (PubMed ID: 30429045)
1. In Vivo PET Tracking of
Man F; Lim L; Volpe A; Gabizon A; Shmeeda H; Draper B; Parente-Pereira AC; Maher J; Blower PJ; Fruhwirth GO; T M de Rosales R
Mol Ther; 2019 Jan; 27(1):219-229. PubMed ID: 30429045
[TBL] [Abstract][Full Text] [Related]
2. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
[TBL] [Abstract][Full Text] [Related]
4. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
5. PET Imaging of Liposomal Glucocorticoids using
Gawne PJ; Clarke F; Turjeman K; Cope AP; Long NJ; Barenholz Y; Terry SYA; de Rosales RTM
Theranostics; 2020; 10(9):3867-3879. PubMed ID: 32226525
[TBL] [Abstract][Full Text] [Related]
6. PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with
Weist MR; Starr R; Aguilar B; Chea J; Miles JK; Poku E; Gerdts E; Yang X; Priceman SJ; Forman SJ; Colcher D; Brown CE; Shively JE
J Nucl Med; 2018 Oct; 59(10):1531-1537. PubMed ID: 29728514
[TBL] [Abstract][Full Text] [Related]
7. A kit formulation for the preparation of [
Man F; Khan AA; Carrascal-Miniño A; Blower PJ; T M de Rosales R
Nucl Med Biol; 2020; 90-91():31-40. PubMed ID: 32979725
[TBL] [Abstract][Full Text] [Related]
8. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
9. Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM
Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190
[TBL] [Abstract][Full Text] [Related]
10. Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy.
Hodgins NO; Al-Jamal WT; Wang JT; Klippstein R; Costa PM; Sosabowski JK; Marshall JF; Maher J; Al-Jamal KT
J Control Release; 2017 Jun; 256():141-152. PubMed ID: 28432037
[TBL] [Abstract][Full Text] [Related]
11. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
12. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
13. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug.
Tanaka Y; Murata-Hirai K; Iwasaki M; Matsumoto K; Hayashi K; Kumagai A; Nada MH; Wang H; Kobayashi H; Kamitakahara H; Okamura H; Sugie T; Minato N; Toi M; Morita CT
Cancer Sci; 2018 Mar; 109(3):587-599. PubMed ID: 29288540
[TBL] [Abstract][Full Text] [Related]
14. A generic
Li N; Yu Z; Pham TT; Blower PJ; Yan R
Int J Nanomedicine; 2017; 12():3281-3294. PubMed ID: 28458546
[TBL] [Abstract][Full Text] [Related]
15. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
[TBL] [Abstract][Full Text] [Related]
16. Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with
Leland P; Kumar D; Nimmagadda S; Bauer SR; Puri RK; Joshi BH
J Transl Med; 2023 Jun; 21(1):367. PubMed ID: 37286997
[TBL] [Abstract][Full Text] [Related]
17. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
18.
Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
[TBL] [Abstract][Full Text] [Related]
19. Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography.
Long Y; Lv X; Song X; Shao F; Ji H; Zhang Y; Qiao P; Liu Q; Xia X; Lei P; Gai Y; Lan X
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4156-4170. PubMed ID: 35790537
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study of
Wang XY; Wang Y; Wu Q; Liu JJ; Liu Y; Pan DH; Qi W; Wang LZ; Yan JJ; Xu YP; Wang GJ; Miao LY; Yu L; Yang M
Acta Pharmacol Sin; 2021 May; 42(5):824-831. PubMed ID: 32901086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
